SCHEMBL3451563

SCHEMBL3451563

COCC(COC)Nc1nc(Nc2ccc(F)c(Cl)c2)ncc1-c1cncc(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 9/20 0.48
SOS1 Q07889 1/20 0.44
STK17A Q9UEE5 2/20 0.42
STK17B O94768 1/20 0.42
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
AURKA O14965 2/20 0.41
JAK2 O60674 1/20 0.41
AURKB Q96GD4 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
XDH P47989 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
AXL P30530 1/20 0.41
EGFR P00533 1/20 0.41
ITK Q08881 1/20 0.41
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448259 0.90 STK17A (0.42) CSNK2A1SOS1STK17ASTK17BABL1
SCHEMBL3448505 0.88 CSNK2A1 (0.57) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3450064 0.88 CSNK2A1 (0.47) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3450777 0.87 CSNK2A1 (0.52) CSNK2A1STK17ASTK17BJAK2ABL1
SCHEMBL13421119 0.86 CSNK2A1 (0.45) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3448386 0.86 CSNK2A1 (0.45) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3457207 0.85 CSNK2A1 (0.48) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3450308 0.83 STK17A (0.51) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL3448962 0.83 STK17A (0.48) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B
SCHEMBL13311591 0.82 CSNK2A1 (0.47) CSNK2A1STK17ASTK17BCSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CSNK2A1 1858/4885SOS1 2048/4885STK17A 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.